Doctors working on better HPV vaccination coverage for pre-teens and teens
The vaccine for Human Papilloma Virus, according to recent studies, is working better than expected, even though vaccination rates in both Connecticut and the country are stagnating well below the target rate. To increase those rates, health experts are recommending doctors urge parents to get the vaccine for their pre-teens and teenagers as part of a back-to-school checkup.Source: Fox 61
Yale OBGYN Research Highlighted in ASCO's 14th Annual Report on Progress Against Cancer
Advance of the Year: Progress in Treating Rare Cancers This year, ASCO names Progress in Treating Rare Cancers as the Advance of the Year. In the United States, rare cancers account for approximately 20% of all cancers diagnosed each year, and incidence rates vary worldwide. Progress has historically lagged behind the achievements made in more common cancers; however, five major studies this past year offer significant steps forward, making this a notable year for advances in rare cancers. Research from the Yale School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences was selected as #4: Trastuzumab effective for a rare form of endometrial cancer.Source: Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
AACR Molecular Cancer Therapeutics: TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Chemoresistance is a major hurdle in the management of patients with epithelial ovarian cancer and is responsible for its high mortality. Studies have shown that chemoresistance is due to the presence of a subgroup of cancer cells with stemness properties and a high capacity for tumor repair. We have developed a library of super-benzopyran analogues to generate potent compounds that can induce cell death in chemoresistant cancer stem cells.Source: Molecular Cancer Therapeutics
British Journal of Cancer: Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair
Platinum resistance may be attributable to inherent or acquired proficiency in homologous recombination repair (HRR) in epithelial ovarian cancer (EOC). The objective of this study was to evaluate the efficacy of the small molecule inhibitor triapine to disrupt HRR and sensitise BRCA wild-type EOC cells to platinum-based combination therapy in vitro and in vivo.Source: British Journal of Cancer
Five Yale researchers awarded grants to study women’s reproductive cancers
Five researchers from the Yale School of Medicine have received grants from Discovery to Cure, a program at the Department of Obstetrics, Gynecology, and Reproductive Sciences that advances the prevention, early detection, and treatment of women’s reproductive cancers such as ovarian, uterine, cervical, vaginal, and vulvar cancers.
New Yale-Novogen Venture to Develop Powerful Treatment for Ovarian Cancer
A new joint venture, CanTx, Inc., has a simple mission: cure ovarian cancer. The venture—announced on Nov. 6—brings together the research advances of Gil Mor, Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale University, the first researcher to isolate and clone ovarian cancer stem cells, with Novogen, an Australian-US biotech company that has developed compounds that target these cancer cells.
Relatives, cancer survivors raise $150,000 at Yale event
It’s been eight years since the love of his life succumbed to cancer, but for Jacques Dickinson the pain is still fresh. Dickinson teared up as he addressed more than 700 people Sunday morning at the Yale Commons who came out to raise money for an event called Discovery to Cure, which helps fund the gynecologic cancer research unit at the Yale University School of Medicine.Source: New Haven Register